The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …

The introduction of tyrosine kinase inhibitors (TKIs) directed against the catalytic activity of
the ABL tyrosine kinase has considerably improved the outcome of chronic myeloid …

The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …

Chronic myeloid leukemia (CML) results from the reciprocal translocation between the long
arms of chromosomes 9 and 22. The translocation, t (9; 22)(q34; q11. 2) is referred to as the …

The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …

The constitutively active BCR-ABL1 tyrosine kinase, found in t (9; 22)(q34; q11)
chromosomal translocation-derived leukemia, initiates an extremely complex signaling …

The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has
proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

BCR-ABL1 plays a key role in the pathogenesis of chronic myeloid leukemia (CML), and it
has been investigated as a druggable target of tyrosine kinase inhibitors (TKIs) over two …

Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent
hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a …